I
n the current issue of Cellular & Molecular Immunology, Cai et al. 1 demonstrate that IL-17A-producing CD4 T (Th17) cells induce graft-versushost disease (GvHD), whereas the IL-17A cytokine is protective in GvHD after allogeneic bone marrow transplantation (allo-BMT). This study clarifies the role of Th17 cells and IL-17A in GvHD and identifies a valid concern about targeting Th17 cells via IL-17A blockade for GvHD prevention.
Th17 cells are derived from the CD4 T-cell lineage and can produce cytokines such as IL-17A, IL-17F, IL-21 and IL-22, among others. The combination of the cytokines TGFβ, IL-6 and IL-1β promotes Th17 cell differentiation, which requires the transcription factor RORγt. Th17 cells play an important role in host defense and in inflammation in autoimmune diseases. 2 The pathogenicity of Th17 cells or IL-17A in GvHD has not been clearly defined. To study the role of Th17 cells in GvHD pathogenicity, genetic deficiency of RORγt or IL-17A was used to block Th17 cell differentiation. Yu et al. 3 found that donor T cells deficient in RORγt had a normal ability to cause GvHD. By contrast, donor T cells deficient in both Tbet and RORγt exhibited an impaired ability to induce GvHD, as both Th1 and Th17 cell differentiation was blocked. However, by using RORγt − / − CD25 − T cells, Fulton et al. 4 demonstrated that impaired Th17 cell differentiation resulted in significantly attenuated GvHD, suggesting that RORγt deficiency may affect the function of regulatory T (Treg) cells. Similarly, Kappel et al. 5 found that IL-17A − / − CD4 T cells, but not total T cells, exhibited a reduced ability to induce GvHD; this effect was associated with lower levels of IFNγ production by CD4 T cells, macrophages, and granulocytes during the early stage of BMT. By contrast, when Yi et al. 6 transferred IL-17A − / − splenocytes or T cells into sub-lethally irradiated recipients, IL-17A deficiency augmented GvHD lethality and increased Th1 cell differentiation in recipients. They illustrated a protective role of IL-17A in the repression of Th1 cell differentiation by regulating host dendritic cells. Differences in the cytokine environment caused by different radiation intensities and different kinetics of GvHD development in different models of allo-BMT may affect whether Th17 cells and IL-17A play pro-or antiinflammatory roles in GvHD.
By using in vitro cytokine-polarized Th17 cells, two groups found that Th17 can induce GvHD, specifically in the skin and lungs. IL-17A is required for the pathogenicity of these Th17 cells in GvHD. 7, 8 However, the plasticity and instability of in vitro polarized Th17 cells, specifically their ability to switch to IFNγ-producing cells, may limit our understanding of the role of Th17 cells in the development of GvHD.
Cai et al. confirmed that IL-17A deficiency in donor CD4 T cells attenuated GvHD severity. However, in the same model of BMT, IL-17A deficiency in donor BM and splenocytes significantly exacerbated GvHD severity. They found that IL-17A deficiency in donor grafts led to IFNγ production and donor macrophage infiltration in GvHD target organs. It seems that IL-17A plays pleiotropic roles in GvHD, with autocrine IL-17A promoting CD4 T-cell activation and Th1 cell differentiation whereas systemic IL-17A protecting against tissue inflammation. The protective role of IL-17A in GvHD could be because (1) Th17 cells have both protective and pathogenic functions. Although IL-17A and IL-17F are the major cytokines produced by Th17 cells, protective Th17 cells also secrete IL-10 and TGFβ, whereas pathogenic Th17 cells produce IFNγ and GM-CSF. 9 Therefore, the combination of the co-secreted cytokines and not IL-17A alone will determine the pathogenicity of Th17 cells in GvHD. It is also not clear whether BM-derived non-alloreactive CD4 T cells may preferentially differentiate into protective Th17 cells. (2) Th17 cells are not the sole cell subset to produce IL-17A. In the mouse spleen, 60% of IL-17A is produced by γδ T cells, 25% is produced by NKT-like cells and 15% is produced by CD4 T cells. In addition, CD8 T cells, T follicular helper (Tfh) cells, mast cells, NK cells, eosinophils, neutrophils and Treg cells can also produce IL-17A. How these IL-17-producing cells regulate GvHD development is not clear. (3) IL-17A plays a protective role in the gut. Ustekinumab, a human IL-12/23p40 mAb, can effectively control moderate to severe Crohn's disease and showed promise in targeting IL-17A to modulate this disease. Paradoxically, secukinumab, a human anti-IL-17A mAb, exacerbated Crohn's disease in a clinical trial. In a T-cell transfer murine model of colitis, IL-17A − / − T cells induced more severe disease by enhancing Th1 cytokine production in colon tissue. In addition to modulating Th1 cell differentiation, IL-17A improves barrier function by strengthening tight junctions, and IL-22 promotes epithelial cell regeneration, which may contribute to the protective role of the IL-17 pathway in the gut. 9 Inhibiting Th1 and Th17 cell differentiation with an anti-IL-12/23p40 mAb has been shown to reduce the severity of acute and chronic GvHD in murine models of allo-BMT and resulted in clinical remission in one patient with advanced, refractory GvHD. 10, 11 These studies suggest that simultaneously targeting both the Th1 and Th17 cell lineage may be more effective than targeting IL-17A alone. Blocking cytokines other than IL-17A produced by Th17 cells has been studied in GvHD. IL-21 blockade alleviated GvHD severity by increasing iTreg cell differentiation. 12 IL-22 expressed in donor T cells contributes to GvHD severity by restraining iTreg cell differentiation. 13 However, IL-22 protects intestinal stem cells, and IL-22 deficiency in recipients accelerated GvHD. 14 In addition to IL-17A, Th17 cells can produce IL-17F, which shares the highest homology to IL-17A in the IL-17 family of cytokines. In dextran sodium sulfate-induced colitis, increased severity of the disease was found in IL-17A − / − mice, but alleviated gut damage was observed in IL-17F − / − mice. 15 Whether IL-17F is pathogenic in GvHD has not been determined. Using tissue-specific IL-17A receptor KO mice as the host or donor in allo-BMT will determine the cell populations responding to IL-17A in GvHD. In addition, IL-17A also contributes to germinal center formation, and Tfh and Th17 cells are the major source of IL-21. 2 Thus, the role of Th17 and IL-17A in chronic GvHD pathogenicity is also an interesting topic of research.
In general, Th17 cells are important for mucosal immunity against specific pathogen invasion, and IL-17A is produced in the healthy gut. Therefore, naturally derived Th17 cells likely play a more regulatory role, as they are important for host defense and mucosal homeostasis maintenance. Instead of cytokine-polarized Th17 cells, how naturally derived Th17 cells regulate GvHD needs to be addressed further. Under disease conditions, a local environment with pro-inflammatory cytokines will promote pathogenic Th17 cell differentiation. Secukinumab has been proven to be effective in Th17 cell-involved autoimmune diseases, such as psoriasis and rheumatoid arthritis, and is being tested in a phase II clinical trial for multiple sclerosis. 9 However, the paradoxical exacerbation of Crohn's disease in patients treated with secukinumab indicates that caution is necessary in targeting IL-17A for GvHD prevention, in which gut pathology is involved. Therefore, although IL-17A-producing CD4 T cells are correlated with human GvHD, targeting IL-17A may not be an effective approach for controlling the pathogenicity of Th17 cells. Further study to uncover specific therapeutic targets for controlling pathogenic Th17 cells is highly warranted.
